Pricing & policy · first seen 3h ago, updated 3h ago
Bristol Myers Squibb patents new NIK inhibitors
Bristol Myers Squibb Co. has disclosed mitogen-activated protein kinase kinase kinase 14 (MAP3K14; NIK) inhibitors potentially useful for the treatment of rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Inflammatory…
Summary from BioWorld Articles.
Coverage 1 article · 1 outlet
-
BioWorld ArticlesBristol Myers Squibb patents new NIK inhibitors